Web Results
www.eurekaselect.com/node/175103

Sep 25, 2019 ... PARP inhibitors are clinically used to treat recurrent ovarian cancer and show significant efficacy in ovarian cancer patients with ...

www.slideshare.net/bkling/the-changing-role-of-parp-inhibitors-in-the-treatment-of-ovarian-cancer

The Changing Role of PARP Inhibitors in the Treatment of Ovarian Cancer ... In recent years, researchers have been looking into using a class of drugs called PARP ...

www.semanticscholar.org/paper/PARP-Inhibitors-and-the-Evolving-Landscape-of-A-Cook-Tinker/713437b03feee5dca55dbbd4bf3b2e76477f0a62

PARP inhibition exploits this cancer vulnerability by further disrupting DNA repair, thus leading to genomic catastrophe. Early clinical data demonstrated ...

link.springer.com/article/10.1007/s11912-020-0873-4

Feb 17, 2020 ... PARP inhibitors are leading to dramatic changes in the standard of care for ovarian cancer, especially among BRCAm patients and those with HRD.

seekingalpha.com/article/4213607-cancer-research-highlight-parp-inhibition-sets-new-benchmark-for-ovarian-cancer

Oct 24, 2018 ... AstraZeneca's PARP inhibitor is currently a bully in the market. ... BRCA-mutant ovarian cancer who responded to chemotherapy and gave them ...

www.clinicaloptions.com/oncology/programs/parp-inhibitors-in-ovarian-cancer/module/text-module/page-1

Dec 3, 2020 ... Currently in ovarian cancer, there are 9 indications for PARP inhibitors: 3 in first-line maintenance treatment, 3 in maintenance for recurrent ...

www.youtube.com/watch?v=r54DgnXLvmI

Precision Medicine in Ovarian Cancer With PARP Inhibitor Therapy and Companion Diagnostics. 446 views · 1 year ago.

www.statnews.com/sponsor/2019/11/04/the-science-behind-parp-inhibitors-and-their-role-in-ovarian-cancer-treatment

Nov 4, 2019 ... In the United States, ovarian cancer is the fifth highest cause of cancer ... prospects of PARP inhibitor clinical trials in ovarian cancer.

www.wndu.com/2021/05/07/parp-inhibitors-reducing-ovarian-cancer-recurrence-risk

May 7, 2021 ... Clinical trials have shown a new medication is revealing promising results for delaying ovarian cancer recurrence.

www.researchtopractice.com/GynOnc19/PARP/Video/1

Role of PARP Inhibition in the Management of Relapsed Ovarian Cancer. DR LEDERMANN: So this is where it all started. All the work in ovarian cancer has been ...